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Pediatric patientAn increased risk of valproate-induced toxicity has been reported in children, particularly in those younger than
2 years of age. Signiﬁcant variations in valproate pharmacokinetics and shifts in themetabolic pathways towards
CYP2C9-dependentmetabolism seem to play some role in the age-related differences in the incidence of adverse
events. We present the case of a premature patient with moderate hemorrhage in the subependymal region
(grade II — intraventricular hemorrhage without ventricular dilatation), several myoclonic episodes in her
right upper arm (series of jerks lasting milliseconds), and epileptiform abnormalities on the EEG (localized
spike-and-wave in the left frontal region with preserved background activity who was treated with valproate.
Serious side effects, consisting of bone marrow depression, hyperammonemia, and serum alkaline phosphatase
elevation, were observed seventeen days after the beginning of valproate therapy. The toxic symptoms were
likely the consequence of a reduced ability to metabolize valproate. The patient was demonstrated to carry
two loss-of-function mutations in CYP2C9 (CYP2C9*3/*3) resulting in exaggerated blood concentrations of
valproate. The present case highlights the importance of assaying inborn errors in CYP2C9 gene in pediatric
patients to avoid valproate-evoked serious side effects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Valproate, a mainstay of antiepileptic therapy, is well tolerated in
most patients; however, serious side effects (hepatotoxicity, hemato-
logic disorders, hyperammonemic encephalopathy, and teratogenic ef-
fects) can rarely occur. Most cases of valproate-evoked hepatotoxicity
have been reported primarily in children younger than 2 years of age.
Although the pathogenesis of valproate-induced toxicity is not clearly
understood, pharmacokinetic and metabolic variations are assumed to
be associated with an increased risk of adverse effects in children [1].
In adults, valproate metabolism involves three major pathways,
glucuronidation, mitochondrial β-oxidation, and cytochrome P450
(CYP)-dependent oxidation, resulting in glucuronide-conjugated, un-
saturated, and hydroxylated metabolites [1]. The valproate metabolism
seems to be shifted towards CYP-mediated pathways in children
because of the poorly developed glucuronidation and inhibition of
mitochondrial β-oxidation by chronic administration of valproate [2].Budapest, Hungary.
nostory).
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A 10-day-old premature girl (born weighing 1850 g and in the 31st
week) was admitted to the department of Internal Medicine for Infants,
Heim Pál Children's Hospital (Budapest, Hungary). Her medical history
at the Perinatal Intensive Centre included moderate hemorrhage in
the subependymal region (grade II — intraventricular hemorrhage
without ventricular dilatation), several myoclonic episodes in her
right upper arm (series of jerks lasting milliseconds), and epileptiform
abnormalities on the EEG (localized spike-and-wave in the left frontal
region with preserved background activity). The patient was treated
with phenobarbital (2 mg/kg) on the 7th day of age. Because there is a
high risk of serious cognitive effects impacting attention and memory
in children from chronic and long-termphenobarbital treatment, we re-
placed phenobarbital with valproate with the target dose of 30 mg/kg
for the premature patient. Seventeen days after the beginning of
valproate therapy, the patient displayed signs of bone marrow depres-
sion (hematocrit: 17.7%, hemoglobin: 59 g/l, white blood cell count:
5.1 × 109/l, platelet count: 39 × 109/l), hyperammonemia (92 μmol/l),
and serum alkaline phosphatase elevation (1695 units/l). The toxic
symptoms were attributed to the valproate treatment; therefore, it
was promptly and completely terminated. Ten days after withdrawal,
the serum level of valproate was still as high as 19.5 μg/ml, which wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hemoglobin level was ameliorated by transfusion of a leucodepleted
red-blood-cell concentrate, whereas platelet count and white blood
cell countwere spontaneously normalizedwithin 6 days. The blood am-
monia level and serum alkaline phosphatase were gradually recovered
after 10 days and 1 month, respectively.
3. Discussion
Glucuronidation is poorly developed in neonates and young
children, whereasmitochondrial β-oxidation activity has been reported
to be compromised by valproate and some of its metabolites. As a
consequence, CYP-catalyzed oxidation, with the major contribution
from CYP2C9, becomes the principal route of metabolism in pediatric
patients [2]. It inspired us to identify the loss-of-function mutations in
CYP2C9 genes in this premature patient. CYP2C9 genotyping for the
polymorphic CYP2C9*2 and CYP2C9*3 alleles was performed retrospec-
tively in the patient's peripheral blood sample, according to the
methods of Temesvári et al. [3]. The assay revealed the homozygous
mutant CYP2C9*3/*3 genotype which can account for the substantially
reduced ability of the child to metabolize valproate. Although the
serum concentration of valproate was assayed after the termination of
valproate treatment, on the basis of the high level measured ten days
after withdrawal, we assumed extremely high exposure during the
valproate therapy which we attributed to the poor metabolism of
valproate as a consequence of the homozygous mutant CYP2C9
genotype. The exaggerated blood concentration was likely the cause of
toxic symptoms in the premature girl.
Valproate is routinely initiated at low dosages (10–15 mg/kg), and
the target doses are subsequently titrated until the optimal clinical
response is achieved. Valproate blood concentrations are generally
assayed three to four weeks after the beginning of therapy; thus,
symptoms, adverse reactions, and ineffectiveness can inform clinicians
about valproate misdosing in the early period of therapy. Compared to
dosing based on symptoms, the dosing based on the status of CYP2C9
has been reported to reduce the incidence of exaggerated valproateblood concentrations, increased serum alkaline phosphatase activity,
and valproate-evoked serious side effects, notably hyperammonemia,
in children [4]. Therefore, allelic variants in the CYP2C9 gene should be
assayed before the beginning of antiepileptic therapy in pediatric
patients.
Because the prevalence of patients with two polymorphic CYP2C9
alleles (CYP2C9*2/*2, CYP2C9*3/*3 or CYP2C9*2/*3) is relatively high in
European white populations (approximately 2–10%), clinicians should
be vigilant for pediatric patients with two loss-of-function CYP2C9
alleles. To avoid serious adverse reactions as a consequence of inborn
errors in valproate metabolism, nonvalproate antiepileptic therapy can
be proposed for children with two mutated CYP2C9 alleles.Acknowledgments
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